Characterization of Naturally Acquired Immunity to a Panel of Antigens Expressed in Mature


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2021
Historique:
received: 12 09 2021
accepted: 25 10 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 29 1 2022
Statut: epublish

Résumé

Naturally acquired immune responses against antigens expressed on the surface of mature gametocytes develop in individuals living in malaria-endemic areas. Evidence suggests that such anti-gametocyte immunity can block the development of the parasite in the mosquito, thus playing a role in interrupting transmission. A better comprehension of naturally acquired immunity to these gametocyte antigens can aid the development of transmission-blocking vaccines and improve our understanding of the human infectious reservoir. Antigens expressed on the surface of mature gametocytes that had not previously been widely studied for evidence of naturally acquired immunity were identified for protein expression alongside Pfs230-C using either the mammalian HEK293E or the wheat germ cell-free expression systems. Where there was sequence variation in the candidate antigens (3D7 Of the 25 antigens selected, seven antigens were produced successfully as recombinant proteins, with one variant antigen, giving a total of eight proteins for evaluation. Antibodies to the candidate antigens were detectable in the study population (N = 216), with seroprevalence ranging from 37.0% (95% CI: 30.6%, 43.9%) for PSOP1 to 77.8% (95% CI: 71.6%, 83.1%) for G377 (3D7 variant). Responses to AMA1 and GE were more prevalent than those to the gametocyte proteins at 87.9% (95% CI: 82.8%, 91.9%) and 88.3% (95% CI: 83.1%, 92.4%), respectively. Additionally, both antibody levels and breadth of antibody responses were associated with age and concurrent parasitaemia. Age and concurrent parasitaemia remain important determinants of naturally acquired immunity to gametocyte antigens. Furthermore, we identify novel candidates for transmission-blocking activity evaluation.

Identifiants

pubmed: 34869075
doi: 10.3389/fcimb.2021.774537
pmc: PMC8633105
doi:

Substances chimiques

Antibodies, Protozoan 0
Antigens, Protozoan 0
Protozoan Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

774537

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00227X/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Muthui, Takashima, Omondi, Kinya, Muasya, Nagaoka, Mwai, Orindi, Wambua, Bousema, Drakeley, Blagborough, Marsh, Bejon and Kapulu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Malar J. 2004 Jun 17;3:18
pubmed: 15202944
Nucleic Acids Res. 2016 Jul 27;44(13):6087-101
pubmed: 27298255
J Infect. 2015 Jul;71(1):117-27
pubmed: 25869538
Infect Immun. 2015 Nov;83(11):4229-36
pubmed: 26283330
Infect Immun. 2011 Dec;79(12):4957-64
pubmed: 21969000
Parasite Immunol. 1990 Sep;12(5):447-56
pubmed: 2255558
PLoS One. 2010 Jun 29;5(6):e11358
pubmed: 20613877
Wellcome Open Res. 2019 Apr 5;4:66
pubmed: 31223663
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5108-13
pubmed: 15792998
Parasite Immunol. 1988 Mar;10(2):209-18
pubmed: 3287282
Mol Biochem Parasitol. 1995 Nov;74(2):143-56
pubmed: 8719156
Nat Commun. 2018 Feb 8;9(1):558
pubmed: 29422648
Mol Biochem Parasitol. 2004 Sep;137(1):35-41
pubmed: 15279949
PLoS Med. 2016 Jun 28;13(6):e1002047
pubmed: 27352303
Infect Immun. 2016 Mar 24;84(4):950-963
pubmed: 26787721
PLoS One. 2015 Apr 01;10(4):e0123102
pubmed: 25830351
Am J Trop Med Hyg. 1995 Mar;52(3):201-6
pubmed: 7694959
PLoS One. 2010 Nov 29;5(11):e14114
pubmed: 21124765
Malar J. 2016 Apr 14;15:213
pubmed: 27075879
PLoS One. 2015 May 21;10(5):e0126747
pubmed: 25996916
Curr Opin Infect Dis. 2017 Oct;30(5):463-470
pubmed: 28731898
Parasite Immunol. 2007 Jun;29(6):309-17
pubmed: 17518949
Lancet Infect Dis. 2012 Jun;12(6):457-68
pubmed: 22445352
Infect Immun. 2008 May;76(5):2240-8
pubmed: 18316390
Parasitology. 2007 Dec;134(Pt.14):1911-29
pubmed: 17714601
BMC Med. 2014 Jul 01;12:108
pubmed: 24980799
BMC Med. 2015 Aug 06;13:183
pubmed: 26248615
J Protozool. 1992 May-Jun;39(3):429-32
pubmed: 1640389
J Infect Dis. 2005 Jun 1;191(11):1932-9
pubmed: 15871128
Infect Immun. 1987 Feb;55(2):369-72
pubmed: 2879793
Ann Trop Med Parasitol. 1991 Aug;85(4):377-85
pubmed: 1796877
J Infect Dis. 2005 Jul 1;192(1):178-86
pubmed: 15942909
Clin Exp Immunol. 1992 Dec;90(3):357-62
pubmed: 1458672
Front Immunol. 2019 Oct 22;10:2480
pubmed: 31695697
Vaccine. 2004 Dec 16;23(5):718-28
pubmed: 15542195
Malar J. 2014 Nov 22;13:451
pubmed: 25416454
Parasit Vectors. 2018 Jan 5;11(1):13
pubmed: 29304870
Parasitology. 2016 Feb;143(2):187-98
pubmed: 26743529
Sci Rep. 2017 Aug 22;7(1):9123
pubmed: 28831122
Front Immunol. 2021 Feb 03;11:609474
pubmed: 33633729
PLoS Pathog. 2018 May 9;14(5):e1007034
pubmed: 29742161
PLoS Clin Trials. 2006 Oct 20;1(6):e29
pubmed: 17053830
Cell Host Microbe. 2018 Jul 11;24(1):43-56
pubmed: 30001524
Cell. 2005 Jun 3;121(5):675-87
pubmed: 15935755
J Infect Dis. 2002 Mar 15;185(6):820-7
pubmed: 11920300
Nat Commun. 2017 Oct 26;8(1):1133
pubmed: 29074880
Malar J. 2017 Aug 1;16(1):306
pubmed: 28764709
Am J Trop Med Hyg. 2006 Mar;74(3):425-31
pubmed: 16525101
Malar J. 2016 Nov 8;15(1):539
pubmed: 27821171
PLoS One. 2013 Nov 18;8(11):e79323
pubmed: 24260195

Auteurs

Michelle K Muthui (MK)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

Eizo Takashima (E)

Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.

Brian R Omondi (BR)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

Christine Kinya (C)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

William I Muasya (WI)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

Hikaru Nagaoka (H)

Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.

Kennedy W Mwai (KW)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Benedict Orindi (B)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

Juliana Wambua (J)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.

Teun Bousema (T)

Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, Netherlands.

Chris Drakeley (C)

Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Andrew M Blagborough (AM)

Division of Microbiology and Parasitology, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge, United Kingdom.

Kevin Marsh (K)

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Philip Bejon (P)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Melissa C Kapulu (MC)

Department of Biosciences, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH